AXS-17

AXS-17, also known as BAER-101 or as AZD-7325, is a GABA_A receptor positive allosteric modulator and nonbenzodiazepine which is under development for the treatment of anxiety disorders and absence epilepsy.^[1][2][3] It is or was also under development for autism spectrum disorder, fragile X syndrome, and other neurological disorders, but no recent development has been reported for these indications.^[2]

Other namesAXS17; BAER101; AZD7325; AZ-7325; AZ7325

Drug classGABA_A receptor positive allosteric modulator; Nonbenzodiazepine

ATC code

• None

CAS Number

• 942437-37-8

Quick facts Clinical data, Other names ...

AXS-17

Clinical data
Other names	AXS17; BAER101; AZD7325; AZ-7325; AZ7325
Drug class	GABAA receptor positive allosteric modulator; Nonbenzodiazepine
ATC code	None
Identifiers
IUPAC name 4-amino-8-(2-fluoro-6-methoxyphenyl)-N-propylcinnoline-3-carboxamide
CAS Number	942437-37-8
PubChem CID	23581869
DrugBank	DB13994
ChemSpider	26334679
UNII	KNM216XOUH
ChEMBL	ChEMBL1783282
Chemical and physical data
Formula	C19H19FN4O2
Molar mass	354.385 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCNC(=O)C1=NN=C2C(=C1N)C=CC=C2C3=C(C=CC=C3F)OC
InChI InChI=1S/C19H19FN4O2/c1-3-10-22-19(25)18-16(21)12-7-4-6-11(17(12)23-24-18)15-13(20)8-5-9-14(15)26-2/h4-9H,3,10H2,1-2H3,(H2,21,23)(H,22,25) Key:KYDURMHFWXCKMW-UHFFFAOYSA-N

Close

The drug is a GABA_A receptor α₂ and α₃ subunit-selective partial positive allosteric modulator acting via the benzodiazepine site.^[2][1][3] It might have reduced side effects compared to non-selective high-efficacy positive allosteric modulators like the benzodiazepines diazepam and lorazepam.^[4] In terms of chemical structure, AXS-17 is a cinnoline derivative.^[1]

AXS-17 was originated by AstraZeneca and the University College London.^[2] It was licensed and under development by Avenue Therapeutics's Baergic Bio, but was later acquired by Axsome Therapeutics, which is now developing the drug.^[2][5] As of November 2025, AXS-17 is in phase 2 clinical trials for anxiety disorders and is in the preclinical research stage of development for absence epilepsy.^[2] AXS-17 was first described in the scientific literature by at least 2012.^[6][4]